Search Results: 1 - 10 of 100 matches for " "
All listed articles are free for downloading (OA Articles)
Page 1 /100
Display every page Item
Therapeutic Acupunctural Resonance II: New Discoveries That Justify the Outcomes of This New Therapeutic Modality  [PDF]
Adrián ángelInchauspe
Journal of Biosciences and Medicines (JBM) , 2016, DOI: 10.4236/jbm.2016.46006
Therapeutic Acupunctural Resonance was first introduced in the academic field in 2015 and was positively welcomed by colleagues all around the world. However, I have decided to do further research going deeply into new and more precise explanations which no longer refer to the effects of this particular treatment, but to how this technique works in the practice of Chinese Medicine. Being able to understand Therapeutic Acupunctural Resonance implies analyzing a series of phenomena related to historic landmarks of Classical Physics, as well as avant-garde theories within Quantum Physics and its theory of fields.
Citability of Original Research and Reviews in Journals and Their Sponsored Supplements  [PDF]
Leslie Citrome
PLOS ONE , 2012, DOI: 10.1371/journal.pone.0009876
Abstract: The contents of pharmaceutical industry sponsored supplements to medical journals are perceived to be less credible than the contents of their parent journals. It is unknown if their contents are cited as often. The objective of this study was to quantify the citability of original research and reviews contained in supplements and compare it with that for the parent journal.
Value of therapeutic equivalence in substitution of original drug with generic by example of fosinipril  [cached]
N.P. Kutishenko,S.Yu. Martsevich,Zh.D. Kobalava,Е.К. Shavarova
Rational Pharmacotherapy in Cardiology , 2011,
Abstract: Aim. To study the therapeutic equivalence of original and generic fosinopril in patients with arterial hypertension (HT) of 1-2 degrees, and to evaluate the cost effectiveness of original drug substitution with generic.Material and methods. Patients (n=36) with HT of 1-2 degree aged 41-82 years and disease duration up 3 to 22 years included in an open, crossover, randomized trial. All patients had two courses of treatment: with generic (Fosicard) and the original drug (Monopril); sequence of courses was determined by randomization. Wash-out period (10-14 days) preceded each course. Treatment duration was 6 weeks; drugs were administered QD; initial dose - 10 mg/day. Blood pressure (BP) and heart rate (HR) were evaluated at the end of the wash-out period, and in 2, 4 and 6 weeks of therapy. In case of ineffective BP control (>140/90 mm Hg) hydrochlorothiazide 12.5 mg was added initially and dose fosinopril was increased up to 20 mg/day next.Results. Patients in groups were comparable by basic clinical parameters. Both fosinopril based drugs have comparable antihypertensive effect. Differences between their effect on systolic and diastolic BP as well as HR at all steps of treatment were not significant. The individual analysis revealed a tendency to more pronounced Monopril antihypertensive effect compared with Fosicard, but the differences were not significant. An average dose of Monopril was 11.8±3.9 mg/day, and Fosicard — 13.2±4.7 mg/day (p=0.13); the rate of monotherapy with both drugs of fosinopril at dose of 10 mg/day was similar (in 41% and 44% of patients, respectively); the rate of combined therapies with various composition differed insignificantly. Reduction in BP <140/90 mmHg was recorded at the end of the study in 29 (85.3%) patients treated with Monorpil and in 27 (79.4%) — Fosicard (p=0.52). Both drugs showed a good safety profile.Conclusion. Fosicard or its combination with hydrochlorothiazide is therapeutically equivalent to original drug (Monopril) or its combination with hydrochlorothiazide.
Therapeutic equivalence of original clopidogrel (Plavix) and its generic (Egitromb). Results of comparative randomized cross-over blind study  [cached]
V.V. Yakusevich,A.S. Petrochenko,V.A. Simonov,N.Yu. Levshin
Rational Pharmacotherapy in Cardiology , 2011,
Abstract: Aim. To study therapeutic equivalence (efficacy, safety and tolerability) of original clopidogrel (Plavix) and its generic (Egitromb) in patients of high cardiovascular risk.Material and methods. Thirty one patients with coronary heart disease and indications for clopidogrel therapy were involved into the randomized cross-over blind study. Half of the patients received original clopidogrel (75 mg daily) during the first 2 weeks and then they received generic clopidogrel in the same dose during next 2 weeks. Another half of the patients received the drugs in reverse order. Antiplatelet activity of Plavix and Egitromb was estimated by effects on ADP-induced platelet aggregation initially and after 2 weeks of treatment with each drug. Study blinding was provided by the following approach: doctors of cardiology clinic performed clinical monitoring and drug distribution; coded blood samples for platelet aggregation assessment were studied in independent laboratory of thrombosis; statistical data analysis was performed by biostatistics expert in other research center.Results. 2-week therapy with each drug led to a significant decrease of ADP-induced platelet aggregation which remained low after switching from original drug to generic and vice versa. Aggregation dynamics did not depend on the first administered drug. There were no significant differences between aggregation changes as a result of treatment with original or generic drug. No one adverse event was observed in association with both drugs therapy.Conclusion. Generic drug Egitromb (Egis, Hungary) and original clopidogrel Plavix (Sanofi-Aventis, France) have equivalent antiplatelet effect.
Publication of Original Research in Urologic Journals – A Neglected Orphan?  [PDF]
Jens Mani, Jasmina Makarevi?, Eva Juengel, Hanns Ackermann, Karen Nelson, Axel Haferkamp, Roman A. Blaheta
PLOS ONE , 2012, DOI: 10.1371/journal.pone.0052420
Abstract: The pathophysiologic mechanisms behind urologic disease are increasingly being elucidated. The object of this investigation was to evaluate the publication policies of urologic journals during a period of progressively better understanding and management of urologic disease. Based on the ISI Web of Knowledge Journal Citation Reports and the PubMed database, the number and percentage of original experimental, original clinical, review or commentarial articles published between 2002–2010 in six leading urologic journals were analyzed. “British Journal of Urology International”, “European Urology”, “Urologic Oncology-Seminars and Original Investigations” (“Urologic Oncology”), “Urology”, “The Journal of Urology”, and “World Journal of Urology” were chosen, because these journals publish articles in all four categories. The publication policies of the six journals were very heterogeneous during the time period from 2002 to 2010. The percentage of original experimental and original clinical articles, related to all categories, remained the same in “British Journal of Urology International”, “Urologic Oncology”, “Urology” and “The Journal of Urology”. The percentage of experimental reports in “World Journal of Urology” between 2002–2010 significantly increased from 10 to 20%. A distinct elevation in the percentage of commentarial articles accompanied by a reduction of clinical articles became evident in “European Urology” which significantly correlated with a large increase in the journal’s impact factor. No clearly superior policy could be identified with regard to a general increase in the impact factors from all the journals. The publication policy of urologic journals does not expressly reflect the increase in scientific knowledge, which has occurred over the period 2002–2010. One way of increasing the exposure of urologists to research and expand the interface between experimental and clinical research, would be to enlarge the percentage of experimental articles published. There is no indication that such policy would be detrimental to a journal’s impact factor.
Quality of Pharmaceutical Industry Press Releases Based on Original Research  [PDF]
Bindee Kuriya, Elana C. Schneid, Chaim M. Bell
PLOS ONE , 2008, DOI: 10.1371/journal.pone.0002828
Abstract: Background Press releases are a popular vehicle to disseminate health information to the lay media. While the quality of press releases issued by scientific conferences and medical journals has been questioned, no efforts to assess pharmaceutical industry press releases have been made. Therefore, we sought to systematically examine pharmaceutical company press releases about original research for measures of quality. Methodolgy/Principal Findings Press releases issued by the ten top selling, international pharmaceutical companies in the year 2005 were selected for evaluation. A total of 1028 electronic press releases were issued and 235 were based on original research. More than half (59%) reported results presented at a scientific meeting. Twenty-one percent of releases were not explicit about the source of original data. While harms or adverse events were commonly cited (76%), study limitations were rarely noted (6%). Almost one-third (29%) of releases did not quantify study results. Studies presented in abstract form were subsequently published within at least 20 months in 53% of cases. Conclusions Pharmaceutical company press releases frequently report basic study details. However, readers should be cautioned by the preliminary nature of the data and lack of identified limitations. Methods to improve the reporting and interpretation of drug company press releases are desirable to prevent misleading media coverage.
Research progress of magnetic resonance imaging contrast agents
Guoping Yan,Renxi Zhuo
Chinese Science Bulletin , 2001, DOI: 10.1007/BF03184316
Abstract: Magnetic resonance imaging (MRI) is a clinical diagnostic modality, which has become popular in hospitals around the world. Approximately 30% of MRI exams include the use of contrast agents. The research progress of the paramagnetic resonance imaging contrast agents was described briefly. Three important approaches in the soluble paramagnetic resonance imaging contrast agents design including nonionic, tissue-specific and macromolecular contrast agents were investigated. In addition, the problems in the research and development in future were discussed.
Research on Evolution Mechanism of Technological Original Innovation—With Mutation Theory of Respective  [PDF]
Zhi-Ming Zhu, in-Sheng Li, Tao Chen
Journal of Service Science and Management (JSSM) , 2012, DOI: 10.4236/jssm.2012.51004
Abstract: Technical innovation is the power and resource for the sustainable and healthy development of enterprises, and is re- lated to the improvement of social productivity and the establishment and improvement of national innovation system. Technical innovation is the process of the enterprise using the original knowledge and transforming it into new tech- nology. The input and output of knowledge of (i.e., creating new technology) presents S curve, experiencing the stage of imitating type, fusion type and original type, which is subjected to the synergistic action of institutional arrangements factor and its operating factors. Through the analysis of evolution mechanism of different stages of technological inno- vation stages, this paper verifies the rationality and scientific nature of the theoretical assumptions.
CaMKII inhibitors: from research tools to therapeutic agents  [PDF]
Patricia Pellicena,Howard Schulman
Frontiers in Pharmacology , 2014, DOI: 10.3389/fphar.2014.00021
Abstract: The cardiac field has benefited from the availability of several CaMKII inhibitors serving as research tools to test putative CaMKII pathways associated with cardiovascular physiology and pathophysiology. Successful demonstrations of its critical pathophysiological roles have elevated CaMKII as a key target in heart failure, arrhythmia, and other forms of heart disease. This has caught the attention of the pharmaceutical industry, which is now racing to develop CaMKII inhibitors as safe and effective therapeutic agents. While the first generation of CaMKII inhibitor development is focused on blocking its activity based on ATP binding to its catalytic site, future inhibitors can also target sites affecting its regulation by Ca2+/CaM or translocation to some of its protein substrates. The recent availability of crystal structures of the kinase in the autoinhibited and activated state, and of the dodecameric holoenzyme, provides insights into the mechanism of action of existing inhibitors. It is also accelerating the design and development of better pharmacological inhibitors. This review examines the structure of the kinase and suggests possible sites for its inhibition. It also analyzes the uses and limitations of current research tools. Development of new inhibitors will enable preclinical proof of concept tests and clinical development of successful lead compounds, as well as improved research tools to more accurately examine and extend knowledge of the role of CaMKII in cardiac health and disease.
New research on the original meaning of “Song(颂)”

- , 2018, DOI: 1672-3104(2018)01-0195-10
Abstract: 摘 要: “雅颂”之“颂”是中国古代文学中一个重要概念。根据《说文解字》及其他材料可知,“颂”字本义是“容貌”,后来才假借表“雅颂”“歌颂”之“颂”。“雅颂”之“颂”在先秦的本字是“讼”,它才是探究本义的关键所在。“讼”在《说文解字》中的两个义项为“争”与“ 讼”(歌颂),它们分别引申自早期的“刑狱之讼”与“祭祀之讼”,而这两个早期义项表现的都是“将大事激动地告于上级及众人”的语言行为,由言语内容、言语方式及言语接受者三方面语言要素可以证明这一共同点,而这正是“讼”字最初始的本义。“讼”的相关同源词(“公”组词)在含义上有旺盛(即兴旺繁盛的体性特质),纷动(即不平静的内在态势),迸发(即迸升而高、散发而广的外在趋向)的词义特征,这正与“讼”的最初始本义相契合,具体则体现为此处三类词义特征与上述三方面言语要素的对应,以此可辅证之前对“讼”本义的猜想。在后世,讼的“颂(讼)诗”“颂(讼)扬”义逐渐由原表“容貌”义的“颂”字假借表示,以至最终“颂”被当成了表示两义的本字,而这又导致了学者在解释“颂(讼)诗”时常联系“容貌”“形容”进行发挥,形成了以“容”释“颂(讼)诗”的错误思路。
Abstract: “Song(颂)” is an important concept in Chinese ancient literature. According to Shuowenjiezi and other materials, it could be known that originally, “Song” meant “looks,” and later it presented the meaning of “eulogizing” by rebus ways of hymns and eulogies. In pre-Qin period, "eulogizing” in hymns is presented by “Song(讼),” and in Shuowenjiezi, it has such two original meanings as “dispute” (debate, litigation) and "sing praise of" (in pre-Qin period it refers to “Feng””Ya””Song” in Books of Songs). These two derived respectively from “litigation(狱讼)” and “eulogizing( 讼).” And their original manifestations both refer to the linguistic behavior of “disclosing important things to the superior or populace,” which can be proven by such three language elements as the content, form and recipient of the parole. And here lies the original meaning of “Song.” Relevant paronyms to “Song(讼)” have such semantic features as “vigorous” which refers to its physical feature, “restless” which means its intrinsic state, and “spurting” which is extrinsic tendency. All these happen to match the original meanings of “Song.” Specifically, these three semantic features match the above three elements of parole, which can further testify the previous guess of the original meaning of “Song.” In later ages, “Song(讼)” in odes and eulogy has been gradually represented by “Song(颂)” in “looks(容貌),” so much so that “Song(颂)” is finally taken as the original word with both meanings, which often cause scholars to associate “looks(容貌)” and “description(形容)” when explaining eulogistic poetry or “poetry of Song(颂)”, hence forming the wrong thought of interpreting “eulogy” with “looks.
Page 1 /100
Display every page Item

Copyright © 2008-2017 Open Access Library. All rights reserved.